Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial

• Published in: Clinical therapeutics Vol. 44; no. 4; pp. 508 - 528
• Main Authors: Kook, Hyungdon, Yu, Cheol Woong, Choi, Donghoon, Ahn, Tae Hoon, Chang, Kiyuk, Cho, Jin-Man, Kim, Soo-Joong, Park, Chang Gyu, Cho, Deok-Kyu, Kim, Sang-Hyun, Lee, Han Cheol, Jin, Han-Young, Chae, In-Ho, Kwon, Kihwan, Ahn, Sung Gyun, Kim, Ju Han, Lee, Sang-Rok, Kim, Jeong-Su, Kim, Seok Yeon, Lim, Sang Wook
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2022; Elsevier Limited
• Subjects: Adenosine diphosphate; Ankle; Asymptomatic; Blood pressure; Blood vessels; cilostazol; Clinical trials; Consent; Controlled release; Diabetes; Diabetic retinopathy; Double-blind studies; Drug dosages; Ginkgo biloba; Heart; Ingredients; Intermittent claudication; Internal Medicine; Ischemia; Laboratories; Leaves; Medical imaging; Mortality; Pain; Patients; peripheral arterial disease; Plant extracts; Product returns; Pulmonary embolisms; Safety; Sensation; SID142; Ulcers; Walking; Ginkgo biloba; cilostazol; peripheral arterial disease; SID142

Renexin® is a combination pill of cilostazol and Ginkgo biloba leaf extract that is used for the improvement of ischemic symptoms associated with peripheral arterial disease (PAD). SID142 is a controlled-release tablet of cilostazol (200 mg) and G biloba leaf extract (160 mg) that was developed to a...